Status:

Red

Decision Date:

October 2024

Comments

RED: NICE TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer. (Decision date - August 2023)

RED: NICE TA1038: Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over (decision date March 25)

RED: NICE TA1039: Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (decision date March 25)

RED: NICE TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (decision date March 25)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again